Clenbuterol to Target DUX4 in FSHD

Abroad (travel likely)RecruitingPHASE1

Conditions

Muscular Dystrophy, Facioscapulohumeral

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Kansas Medical Center, Kansas City, Kansas, United States
Contact: Study coordinator (Rebecca Clay, BS) · rclay@kumc.edu · 913-945-9936
Contact: Principal Investigator (Jeffrey Statland)
University of Rochester Medical Center, Rochester, New York, United States
Contact: Study coordinator (Leann Lewis, MSGC) · Leann_Lewis@URMC.Rochester.edu · 585-275-7680
Contact: Principal Investigator (Brianna Brun)
University of Washington, Seattle, Washington, United States
Contact: Study coordinator (Lilly Young) · eyoung8@uw.edu · 206-616-5957
Contact: Study coordinator (Leo Wang)

View source on ClinicalTrials.gov Contact study team (email)